Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQXP | ISIN: IL0011429839 | Ticker-Symbol: 5DT
Tradegate
26.03.24
09:18 Uhr
1,440 Euro
+0,010
+0,70 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENTERA BIO LTD Chart 1 Jahr
5-Tage-Chart
ENTERA BIO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,5001,59020:38
1,5001,59020:17

Aktuelle News zur ENTERA BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEntera Bio Ltd.: Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months62JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides, announced today that The American...
► Artikel lesen
MoOPKO Health (OPK) And Entera Bio Announce Data for GLP-211
08.03.Entera Bio Ltd. - S-8, Securities to be offered to employees in employee benefit plans3
08.03.Entera Bio GAAP EPS of -$0.31 beats by $0.011
08.03.Entera Bio Ltd. - 10-K, Annual Report1
08.03.Entera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates230JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, today reported financial results...
► Artikel lesen
04.03.Entera Bio regains NASDAQ compliance with bid price1
04.03.Entera Bio regains compliance with Nasdaq minimum bid price requirement1
04.03.Entera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement127JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that it received...
► Artikel lesen
04.03.Entera Bio Ltd. - 8-K, Current Report-
02.02.Entera Bio files to sell 16.5M ordinary shares for holders5
02.02.Entera Bio Ltd. - 8-K, Current Report3
30.01.Entera Bio Ltd.: Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference1
12.01.Entera Bio And 3 Other Stocks Under $1 Insiders Are Buying11
03.01.Entera Bio receives extension from Nasdaq to regain compliance with minimum bid price rule5
03.01.Entera Bio Ltd. - 8-K, Current Report3
26.12.23Entera Bio Ltd.: Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 20257
26.12.23Entera Bio Ltd. - 8-K, Current Report3
29.11.23Entera Bio Ltd.: Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform266JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, reported...
► Artikel lesen
14.11.23Entera Bio Flat on Release of Q3 Numbers4
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1